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Abstract
Background: The burden of invasive pneumococcal disease in young children decreased dramatically following
introduction of the 7-valent pneumococcal conjugate vaccine (PCV7). The epidemiology of S. pneumoniae now
reflects infections caused by serotypes not included in PCV7. Recently introduced higher valency pneumococcal
vaccines target the residual burden of invasive and non-invasive infections, including those caused by serotypes
not included in PCV7. This review is based on presentations made at the European Society of Pediatric Infectious
Diseases in June 2011.
Discussion: Surveillance data show increased circulation of the non-PCV7 vaccine serotypes 1, 3, 6A, 6C, 7 F and 19A
in countries with routine vaccination. Preliminary evidence suggests that broadened serotype coverage offered by
higher valency vaccines may be having an effect on invasive disease caused by some of those serotypes, including
19A, 7 F and 6C. Aetiology of community acquired pneumonia remains a difficult clinical diagnosis. However, recent
reports indicate that pneumococcal vaccination has reduced hospitalisations of children for vaccine serotype
pneumonia. Variations in serotype circulation and occurrence of complicated and non-complicated pneumonia caused
by non-PCV7 serotypes highlight the potential of higher valency vaccines to decrease the remaining burden. PCVs
reduce nasopharyngeal carriage and acute otitis media (AOM) caused by vaccine serotypes. Recent investigations of
the interaction between S. pneumoniae and non-typeable H. influenzae suggest that considerable reduction in severe,
complicated AOM infections may be achieved by prevention of early pneumococcal carriage and AOM infections.
Extension of the vaccine serotype spectrum beyond PCV7 may provide additional benefit in preventing the evolution
of AOM. The direct and indirect costs associated with pneumococcal disease are high, thus herd protection and
infections caused by non-vaccine serotypes both have strong effects on the cost effectiveness of pneumococcal
vaccination. Recent evaluations highlight the public health significance of indirect benefits, prevention of pneumonia
and AOM and coverage of non-PCV7 serotypes by higher valency vaccines.
Summary: Routine vaccination has greatly reduced the burden of pneumococcal diseases in children. The
pneumococcal serotypes present in the 7-valent vaccine have greatly diminished among disease isolates. The
prevalence of some non-vaccine serotypes (e.g. 1, 7 F and 19A) has increased. Pneumococcal vaccines with broadened
serotype coverage are likely to continue decreasing the burden of invasive disease, and community acquired
pneumonia in children. Further reductions in pneumococcal carriage and increased prevention of early AOM infections
may prevent the evolution of severe, complicated AOM. Evaluation of the public health benefits of pneumococcal
conjugate vaccines should include consideration of non-invasive pneumococcal infections, indirect effects of
vaccination and broadened serotype coverage.
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Background
The human nasopharynx is the reservoir of Streptococcus
pneumoniae, which is usually carried asymptomatically, and
is transmitted to other individuals by respiratory droplets.
The carriage rate is highest in young children, who most
likely carry pneumococci in the nasopharynx at least one
time, and are the primary source for its spread within a
community. In the host, pneumococci can spread locally
from the nasopharynx to cause otitis media or sinusitis, or
to the lungs to cause pneumonia. Pneumococci can also
cause invasive infections with high mortality. Pneumonia
with empyema or bacteraemia, febrile bacteraemia and
meningitis are the most common invasive pneumococcal
diseases (IPD). In Europe and the US, the risk of infection
is greatest in children younger than 2 years, far from negli-
gible in children under 5 years, declines steadily through
the teens and then increases again after the age of 50 years
[1-4].
The burden of invasive pneumococcal disease in young
children decreased dramatically following the introduction
of the 7-valent pneumococcal conjugate vaccine (PCV7)
into national immunization programs (NIPs) in the US and
a number of EU countries [5,6]. PCV7 contains capsular
polysaccharides from seven S. pneumoniae serotypes
conjugated to CRM197, a non-toxic mutant of diphtheria
toxin. When PCV7 was licensed, those serotypes (4, 6B,
9 V, 14, 18C, 19 F and 23 F), caused the majority of invasive
pneumococcal infections in the US [7] and were also
associated with antibiotic resistance [8,9].
In countries with high vaccination coverage, the epi-
demiology of S. pneumoniae now reflects infections caused
by a limited number of serotypes that were not included in
the 7-valent vaccine. This has partially offset decreases in
vaccine serotype IPD incidence. The global benefit of
PCV7 programs [8,10,11] has not been affected because
the increases in incidence of non-vaccine serotype infec-
tions are small compared with the decreases in incidence of
IPD caused by vaccine serotypes [12,13]. Recently intro-
duced higher-valency PCV formulations (Table 1) are
intended to target the residual burden of IPD, non-invasive
infections (pneumonia and otitis media, especially compli-
cated cases) and infections caused by non-PCV7 serotypes
in children up to 5 years of age.
This review is based on presentations made during a
symposium at ESPID 2011 that provided an update of
ongoing surveillance data, published clinical trials and
effectiveness data evaluating conjugate pneumococcal
vaccines. Our objective is to provide an overview of
pneumococcal diseases including IPD, community-
acquired pneumonia (CAP) and severe AOM in Europe
in the post-PCV7 era.
Impact of conjugate vaccines on pneumococcal
invasive disease
Current epidemiology of invasive pneumococcal disease
in Europe
PCV7 was included in the NIPs, or was recommended for
routine vaccination, in a number of European countries,
between 2006 and 2008 (Table 2). It is administered
concomitant with other childhood vaccines as a 2- or a 3-
dose primary series plus a booster [14]. Recent surveil-
lance data in European countries having a vaccine uptake
of 80-90% indicate that the PCV7 serotypes have nearly
disappeared from IPD isolates in young children [15]. The
data have also demonstrated increased circulation of the
non-PCV7 serotypes 1, 3, 6A, 6C, 7 F and 19A [15]. This
has spurred efforts to confirm the potential benefits of the
broadened serotype coverage offered by recently licensed
higher valency PCV vaccines.
In the UK, PCV7 became part of the NIP in September
2006. A recently published review reported that cumula-
tive weekly reported cases of PCV7 vaccine-serotype IPD
in children <5 years of age fell from 400 in 2006 to 25 in
2010. Cases caused by non-vaccine serotypes increased
from 150 to 375 over the same period, for an overall
reduction in IPD of 150 cases in 2010 compared to 2006
[13]. Reported non-vaccine serotype IPD cases among
children < 2 years of age increased between 2007 and 2010
[10,13,16]. By 2011 they had returned to the numbers
reported in 2008, a decrease that followed the introduction
of the PCV13 vaccine [10,13,16].
PCV7 was introduced in Germany in July 2006. In
children <2 years of age, approximately 100 cases of
vaccine-type IPD were reported annually between 1997
and 2007. Within 2 years after widespread PCV7 vaccin-
ation, approximately 10 cases/year of vaccine-serotype IPD
were reported. Most of these IPD infections occurred in
unvaccinated children or in those too young to be vacci-
nated (German National Reference Center for Streptococci
[GNRCS]; Personal communication, M. van der Linden).
German capture-recapture data show the overall inci-
dence of IPD in those <2 years of age fell from about 20
cases/100 000 child years between 1997 and 2003 to 10/
100 000 between 2007 and 2009 [17] The mean annual
Table 1 Pneumococcal serotypes included in the licensed pneumococcal conjugate vaccines
Vaccine Manufacturer Serotypes Indicated age
PCV7 (Prevenar) Pfizer 4, 6B, 9V, 14, 18C,19F, 23F < 5 years
PCV10 (Synflorix) GSK 4, 6B, 9V, 14, 18C,19F, 23F, 1, 5, 7F, < 5 years
PCV13 (Prevenar 13) Pfizer 4, 6B, 9V, 14, 18C,19F, 23F, 1, 3, 5, 6A, 7F, 19A < 5 years
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incidence of PCV7 serotype IPD was 13.5/100 000 child-
years between 1997 and 2003, 3.5/100 000 in 2007–08
and 2/100 000 in 2008–09. Changes in incidence for
non-PCV7 serotypes were not observed in the first year
after implementation of PCV7 vaccination (approxi-
mately 6.5 cases/100 000), but increases were observed
for some non-PCV7 serotypes, namely 1, 7 F and 19A in
the second year [17,18].
Serotype coverage of higher valency PCV vaccines
Higher valency PCV vaccines have recently been intro-
duced in Europe, first in Germany and subsequently in
Belgium, Denmark, France, Greece, Hungary, Ireland,
Italy, the Netherlands, Norway, Slovakia, Sweden, the
UK and Finland. They are available in Spain and
Portugal, but not yet included in the NIP [14,19]. In
Germany, PCV10 was introduced in April 2009 and
PCV13 was introduced in December 2009. Approxi-
mately half of German children were being given PCV10
in December 2009, when PCV13 was introduced, and by
2011 about 85% were receiving PCV13 (Personal com-
munication M. van der Linden). German IPD surveil-
lance data are available for the non-PCV7 serotypes 1, 3,
5, 6A, 7 F and 19A from 1997 through June 2011. In
2009–2010, before introduction of PCV10, there were
107 reported cases of IPD in children <2 years of age. Of
these, PCV7 serotypes were isolated from 13 cases
(12%), PCV10 serotypes from 40 (37%), and PCV13 ser-
otypes from 73 (68%). The picture was different for
severe AOM in Germany at that time. Higher frequen-
cies of serotype 3, and 19A isolates resulted in slightly
increased coverage, compared to IPD, of the 13-valent
vaccine relative to the 7- or 10-valent vaccines. Thus not
all serotypes were represented in similar proportions in
different types of pneumococcal disease. Reports of chil-
dren having AOM with efflux decreased from 459 in
2008–9 to 213 in 2010–11 as the estimated vaccination
rate increased from 71.9% to 84.5%. Pathogens were
identified in 65 of 213 cases and S. pneumoniae was
found in 12/65 (18.5%) [20]. Vaccine coverage of sero-
types isolated from nasopharyngeal carriage was not
higher than 30% for any of the three available PCV vac-
cines. In the UK during 2011, the cumulative weekly
cases of IPD caused Xby the six new serotypes in PCV13
in children < 2 years of age fell to a lower level than be-
fore introduction of PCV7. Reports of IPD caused by
any serotype not in PCV7 fell to levels similar to those
in 2006 when PCV7 was introduced (Figure 1) [16]. Esti-
mated serotype coverage of PCV7, PCV10 and PCV13
in several European countries is shown in Table 3. Re-
cent data on the serotype distribution of IPD in
European children < 2, < 5 or ≤ 15 years of age are sum-
marized in Table 4.
Decreases in IPD cases caused by the six new vaccine
serotypes contained in PCV13 were also reported in
Germany by capture recapture surveillance. The number
of reported IPD cases caused by serotypes 1, 3, and 7 F
decreased. However, an increase in cases caused by
Table 2 PCV7 adoption in national immunization programs (NIP) or universal vaccination recommended by health
authorities in European countries
Country Introduction in NIP or universal recommendation Schedule
Belgium Jan 2007 2 + 1
Cyprus Sep 2008 3 + 1
Denmark Universal recommendation Oct 2007 2 + 1
France Universal recommendation May 20061 2 + 1 Oct 2008
Germany Universal recommendation Jul 2006 3 + 1
Greece Jan 2006 3 + 1
Hungary Universal recommendation Oct 2008 2 + 1
Ireland Sep 2008 2 + 1
Italy Dec 20062 2 + 1
Luxembourg Feb 2003 3 + 1
Netherlands Jun 2006 3 + 1
Norway Jul 2006 2 + 1
Spain (Madrid)3 Jan 2007 3 + 1
Switzerland Jul 2006 2 + 1
Turkey Jan 2009 3 + 1
UK Sep 2006 2 + 1
1 Limited recommendation in 2003 with 3 + 1 administration schedule.
2. PCV7 was recommended regionally prior to the date of inclusion in the NIP.
3.PCV vaccination recommendation is regional.
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serotype 19A that began in 2006–07 continued until
2010–11, when the rate of increase slowed. The total
number of IPD cases caused by these non-PCV7 sero-
types decreased from 60 in 2009–10 to just over 40
through June 2011, approximately 18 months after ex-
clusive use of PCV13 (Figure 2) [18]. From July-
December 2011 only 6 non-PCV7 serotype cases were
reported (1:n = 1, 3:n = 2, 5:n = 0, 6A:n = 1, 7 F:n = 1,
19A:n = 1) [32]. It is difficult to separate the impacts of
different licensed higher valency vaccines in Germany as
the commercially available vaccines changed (first PCV10
only, then PCV10 and PCV13 concomitantly and finally a
predominance of PCV13. Preliminary evidence, however,
suggests that increased serotype coverage of higher valency
vaccines is having an effect on pneumococcal infections
caused by non-PCV7 serotypes, including those caused by
19A, 7 F and 6C [18,20,32,33].
Pneumococcal conjugate vaccines and community
acquired pneumonia
The burden of CAP in children
Childhood community acquired pneumonia (CAP)
has significant morbidity and mortality. The burden
of CAP in developed countries is 10–15 cases/1000
children per year with an annual hospital admission
rate of 1–4/1000 [34]. The incidence is higher in
children less than 5 years of age; 6-40/1000 com-
pared to 7–16/1000 in children from 5–15 years of
age [34]. Most deaths occur in children younger than
4 years of age [23]. Influenza, respiratory syncitial
virus (RSV) and parainfluenza 1, 2 and 3 are fre-
quent viruses causing CAP; S. pneumoniae is the
most common bacterial cause [35].
The increasing use of pneumococcal vaccines
underscores the need for accurate diagnosis in order
to define the burden of pneumococcal disease and
monitor vaccine effectiveness. However, the clinical
differentiation of pneumonia from other lower re-
spiratory tract infections, such as bronchitis and
bronchiolitis, can be challenging because its clinical
signs and symptoms, including fever, cough and tach-
ypnea are not specific. Often children present at gen-
eral practices where chest X-ray and other diagnostic
methods with increased specificity are not available.
The more defined the clinical endpoint, e.g., lobar
pneumonia, empyema; the smaller the aetiologic di-
versity. Finally, there are much more published data
from children hospitalized with severe or complicated
CAP confirmed by X-ray and from identification of the
aetiologic agent by blood culture than there are from
children with less severe pneumonia.
Figure 1 Pneumococcal isolates of PCV13 vaccine serotypes recovered from children <2 years of age with IPD in Germany [18].
Table 3 Estimated vaccine serotype coverage (%) of IPD
in children < 2 years of age
PCV7 PCV10 PCV13
Belgium (2009)[21] 3 38 69
Netherlands (2006–2008)[22] 35 69 79
France (2008)[23] 11 34 68
Switzerland (2009)[24] 19 36 76
Portugal (2006–08)[25] 18 39 77
Germany (2009–10)[26] 12 37 68
Spain (2009–2010)[27] 4 44 80
Greece (2008–2010)[28] 12 34 73
Austria (2007–09)[29]* 62 77
* Data for Austria are in children <5 years of age.
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Aetiology of childhood CAP
An extended discussion of methodologies used to identify
causative agents of CAP is beyond the scope of this article,
but it is interesting to look briefly at some studies that
have compared blood culture, PCR and serology for esti-
mating the proportion of CAP cases that are attributable
to S. pneumoniae. Blood culture has some well-known
limitations. It is not routinely carried out in either general
practice or hospitals and has a low sensitivity of 10-30% in
childhood CAP, which decreases with prior antibiotic use.
In a prospective study, PCR confirmed pneumococcal
infection in 80 (10.6%) of 753 children hospitalized with
a diagnosis of community acquired bacteremic pneumo-
nia [34]. PCR allowed serotyping in blood samples from
74 of the 80 children (92.5%). More than two-thirds of
those infections were caused by non-PCV7 serotypes,
with serotypes 1, 3 and 19A accounting for more than
half. Serotype 1 was the most frequent serotype (26/80,
32.5%) and was associated with complications (50.0% in
patients with complicated pneumonia versus 18.2% in
patients with uncomplicated pneumonia) and older age.
Serotype 19A was second in frequency (15.0%) and was
associated with younger age. Blood culture and PCR
were performed simultaneously in 292 of the 753
patients. S. pneumoniae was identified in 47 of the 292
by one or both of the methods; in 45/292 (15.4%) by
PCR but only in 11/292 (3.8%) by culture [31].
In another study, serology indicated a pneumococcal
aetiology (titration of anti-pneumococcal pneumolysin
and anti-pneumococcal C-polysaccharide IgG) in 18 of
Table 4 Pneumococcal serotype distribution in children < 2, < 5 or ≤ 15 years old in several European countries
Country 3 most prevalent serotypes Age group
Invasive pneumococcal disease
UK (2008–2009)[30] 7F, 19A, 1 <5 years
France (2008)[23] 19A, 1, 7F ≤15 years
Belgium (2009)[21] 1, 19A, 7F <2 years
Portugal (2006–2008)[25] 1, 19A, 7F ≤5 years
Germany (2009–2010)[26] 7F, 1, 19A <2 years
Greece (2008–2009)[28] 19A, 7F, 3 ≤5 years
Switzerland (2009)[24] 3, 19A, 7F <5 years
Spain (2009–2010)[27] 1, 19A, 7F <15 years
Pneumococcal pneumonia
Italy (2007–2009)[31] 1, 19A, 3 ≤15 years
Belgium (2009)[21] 1, 3, 5 ≤15 years
AOM
Germany (2009–2010)[20] 3, 19A, 19F Not reported
Greece (2008–2009)[28] 19A, 19F, 6A ≤5 years
A B
Figure 2 Cumulative weekly number of reports of IPD in children < 2 years of age in England and Wales by July-June epidemiological
year: 2005 to 2012. A. IPD caused by any of the six PCV13 serotypes B. IPD caused by any pneumococcal serotype but not in PCV7 not in
PCV7. Adapted from: Health Protection Agency, UK. Pneumococcal Disease [16] http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/
Pneumococcal/.
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101 children with CAP (18%), but blood culture was
positive in only one of them [36]. In yet another study of
99 children with CAP, a pneumococcal aetiology was
established in 46% by serology, in 22% by PCR and 1%
by culture [37].
Impact of PCV7 on CAP
The impact of vaccination on CAP incidence can help
define the contribution of pneumococcal vaccine sero-
types to the overall disease burden. In the UK, hospital
admissions for CAP among children younger than
2 years of age rose by 31%, from 1022 to 1340/million
child-years between 1997 and 2006. CAP admissions
then decreased by 19% to 1079/million in the two years
following introduction PCV7 against a background of
increasing hospital admissions of children for RTI [38].
Admissions for CAP also declined during the same
period in older children who had not been vaccinated.
Some of that decrease could have resulted from natural
variation in the disease incidence [39]. However, herd
protection likely accounted for some of the decrease, as
the PCV7 vaccination coverage among those ≤2 years of
age in the UK was at least 84%. Other reports have also
suggested an additional impact of PCV7-vaccination on
CAP incidence through herd protection [40].
In Italy, a retrospective study compared the incidence of
hospital admissions in the first 2 years of life for childhood
CAP in a group born in 2000–2002 before the introduc-
tion of PCV7 with a group born in 2003–2005, after its
introduction [41]. For all-cause pneumonia, the inci-
dence was 64.2/10 000 child-years among those born in
2000–2002 compared with 54.4 for those born in
2003–2005, a vaccine effectiveness of 15.2%. The corre-
sponding results for pneumococcal pneumonia were
1.91 cases/10 000 child years versus 0.56 cases, a vac-
cine effectiveness of 70.5%. Only 2.9% of the all-cause
pneumonia admissions in 2000–2002 were coded as
pneumococcal pneumonia, but a 15.2% reduction in
pneumonia by PCV7 highlights the difficulties in find-
ing an aetiologic diagnosis of childhood CAP.
Empyema: complicated CAP
Empyema is an invasive complication of pneumonia.
The incidence of empyema in children with CAP began
to increase in both North America and in Europe in the
mid to late 1990s. It has continued to increase even in
those countries where PCV7 has been introduced
[42-46]. Studies in Europe and the USA have consist-
ently shown a small number of serotypes - included
in PCV7 to be associated with empyema. The most fre-
quently associated are serotypes 1, 3, 5, 7 F and 19A; which
account for 50 to 85% of empyema cases, and serotype 14,
accounting for up to 13% and occurring in children not
vaccinated with PCV7 [47-50].
Estimated serotype coverage of PCVs in childhood CAP
From what is known of the pneumococcal serotypes
currently associated with childhood CAP [35,51], both
licensed higher valency vaccines have substantially
broader serotype coverage than PCV7, i.e., more than
80% compared with 20-40%. The CAP coverage offered
by PCV7 decreases from about 60% in children younger
than 2 years of age to 40% in those from 2 to 5 years of
age and to approximately 10% in those older than 5 years
[51]. This decrease in estimated coverage did not occur
for the higher valency vaccines among older children.
Coverage was also estimated to be higher in complicated
than in uncomplicated CAP [35]. PCV’s of higher valency
thus have the potential to decrease the remaining burden
of CAP and especially complicated CAP.
To summarize, CAP aetiology remains a difficult clinical
diagnosis with low specificity, and wider use of diagnostic
tools having increased specificity is needed. Consequently,
the prevalence of CAP attributable to S. pneumoniae is
probably underestimated. Recent reports do indicate a con-
tinuous impact of PCV7 on hospitalisations for vaccine
serotype CAP. However, variations in serotype circulation
and occurrence of CAP caused by non-PCV7 serotypes
highlight the potential of higher valency PCVs to decrease
the remaining burden of CAP.
Conjugate pneumococcal vaccines and the aetiology of
acute otitis media (AOM). An unforeseen benefit of
vaccination
In addition to preventing IPD in children, PCVs reduce
the carriage of vaccine serotypes in the nasopharynx,
and reduce AOM caused by those serotypes. Recent
investigations of the interaction between S. pneumoniae
and non-typeable H. influenzae (NTHi) have increased
our knowledge of the role of PCV in the prevention of
AOM, particularly in complicated or difficult to treat
cases.
The majority of AOM are caused by S. pneumoniae
and NTHi [52] with NTHi infections often representing
a secondary/complicated status, rather than causing a
primary infection. Clinical and microbiological evalu-
ation of over 8000 children <5 years of age showed that
risks for NTHi versus S. pneumoniae as a single patho-
gen in AOM include occurrence in winter, bilaterality,
>3 previous episodes and previous antibiotic treatment
for AOM [53]. Mixed AOM infections or those in which
NTHi plays a role are common in recurrent, non-
responsive to antibiotics and chronic otitis media cases,
and are more difficult to treat [54].
Evolution of AOM
The evolution of pneumococcal AOM is thought to
begin most often with pneumococcal colonization and if
local spread occurs with mucosal infection, AOM can
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result. The first cases of AOM are often caused by
pneumococcus and are responsive to antibiotic treat-
ment. Recurrent cases are increasingly likely to involve
NTHi. Some of these cases respond to treatment, but
others become chronic, with increasing likelihood of
NTHi involvement [53-55]. Chronic AOM that does not
eventually resolve with treatment can evolve into serious
otitis media or chronic suppurative otitis media, which
may result in hearing impairment or require tube insertion
or surgery. The aetiology of pneumococcal AOM in over
5000 children in Israel who underwent tympanocentesis or
presented with otorrhea revealed a (38%) rate of mixed
pneumococcal plus NTHi infection, 59% single pneumo-
coccal infections and 3% mixed infections with pneumo-
coccus and other bacteria [56]. Mixed infections were
associated with increasing age, previous AOM episodes,
bilaterality and being a Bedouin child (possibly because of
crowding in extended family households and increased
carriage) [56]. This aetiology of mixed AOM is not unique
to Israel, as mixed pneumococcal and NTHi infections
have been observed in 19%, 29% and 40% of complicated
AOM cases in studies conducted in French, Argentine and
Australian aboriginal children, respectively (Cohen, per-
sonal communication, [57,58]. Determination of bacterial
growth from tube otorrhea samples over an 8-day follow
up of placebo or antibiotic treatment confirmed that single
infection with either H. influenzae or S. pneumoniae
resolved more quickly and were more responsive to anti-
biotics than mixed infections [59]. The patient characteris-
tics, difficulty of treatment and survival advantages in
mixed AOM are suggestive of biofilm formation, which has
also been shown to play a role in other otorhinolaryngologi-
cal infections [60]. In vitro and animal models have shown
that NTHi can passively confer beta-lactam resistance
to S. pneumoniae by forming biofilms or by production
of beta-lactamase [61].
It is likely that NTHi is often associated with a biofilm
formation in the middle ear, especially in conjunction
with an initial S. pneumoniae infection [55,62-64]. The
bacteriologic steps in AOM progression might begin
with a simple S. pneumoniae infection at first. However,
repeated, recurrent and chronic AOM could become
increasingly associated with NTHi and decreasing pro-
portions of S. pneumoniae and with biofilm formation.
The role of PCV
PCV vaccination reduces carriage of the pneumococcal
serotypes that are present in the vaccine and thus pre-
vents local spread that would otherwise cause early
AOM infections [65]. If the incidence of early, simple
AOM is reduced, then one would expect that there
should also be a reduction in mixed and complicated
AOM. In fact, looking again at an early PCV7 efficacy
trial, there was relatively low overall efficacy against any
AOM, but up to nearly a 23% reduction in recurrent
AOM [66]. The importance of timely vaccination to pre-
vent the first cases of AOM is highlighted by reports
that while vaccination of children with a history of
recurrent AOM pneumococcal vaccination reduced
carriage of vaccine serotypes, it did not protect against
subsequent recurrences of AOM [67-69]. A randomized
trial of an investigational PCV11 vaccine has shown (by
microbiological analysis of middle ear fluid) that PCV vac-
cination reduced the incidence of mixed pneumococcal
and NTHi infection by more than 30% [70]. When com-
paring the pathogens recovered from middle ear fluid of
PCV vaccinated versus control children with an epidemi-
ology suggestive of complicated AOM, there were reduc-
tions of 58% in pneumococcal vaccine serotypes, 51% in
non-vaccine serotypes and 35% in H. influenzae, which
would be expected if pneumococcal vaccination reduced
initial AOM infections that eventually became recurrent
or chronic and mixed [70]. The PCV method included an
H. influenzae-derived protein carrier, therefore at least
some role of the NTHi antigen could not be ruled out.
Two other recent observational studies showed that PCV
reduced emergency room visits for AOM with mixed in-
fection and complicated by otorrhea. They also showed
that there were significant reductions in pneumococcal
and NTHi isolates from middle ear fluid compared to
fluid obtained prior to PCV vaccination [71]. Studies that
have reported on the clinical effectiveness of PCV7 against
recurrent, complicated or antibiotic-resistant AOM have
recently been reviewed [72].
Preliminary results from PCV efficacy studies and post
PCV epidemiology data suggest that considerable reduc-
tion of both S. pneumoniae and NTHi infections may be
achieved by prevention of early pneumococcal carriage
and AOM, decreasing the number of children with
severe disease [73]. One study has already shown that
PCV vaccination resulted in 40% reductions in ambula-
tory visits and antibiotic use for AOM [74]. Whether the
presence of the H. influenzae-derived protein D as a car-
rier in PCV10 may further decrease the role of NTHi in
AOM still remains to be seen. Given the evidence for
serotype replacement, extension of the PCV serotype
spectrum beyond PCV7 may provide additional benefit
in prevention the evolution of AOM. Broadened preven-
tion of AOM would have an important effect on cost
effectiveness of vaccination [75-77].
Public health benefits of pneumococcal vaccine
The PCV7 vaccine is licensed in over 90 countries and
widely used, or included in the national immunization
program (NIP), in more than 40 countries [78].
Reduction in the disease burden in vaccinated children
and herd protection together with limited disease caused
by non-vaccine serotypes indicated a favorable cost
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effectiveness ratio that influenced adoption in NIPs
[79-82]. However, the cost effectiveness of PCV7 in the
NIPs in some European countries may now be reduced
by increases in invasive disease caused by non-vaccine
serotypes [16,83-86]. Recent reviews of published PCV7
cost effectiveness evaluations highlight the contributions
of herd protection, prevention of pneumonia and AOM
and vaccine coverage of non-PCV7 serotypes [79,86-89].
In England and Wales, IPD surveillance data revealed that,
despite increased occurrence of non-PCV7 serotype IPD
(primarily caused by 7 F, 19A, and 22 F), the overall inci-
dence of IPD in 2009–10, in those < 2 and> 65 years of
age, was 56% and 19% lower, respectively, than it was be-
fore PCV7 was included in the NIP [89]. The authors con-
cluded that further reductions should follow the use of
higher valency vaccines. Most health economic models
assume the cost of PCV vaccination will be recovered by
future savings [79,88,90]. The direct and indirect costs
associated with pneumococcal disease are high, thus
vaccine serotype infections prevented by herd protection
and cases caused by non-vaccine serotypes have strong
effects on the cost effectiveness of pneumococcal vaccin-
ation in NIPs.
In the first 5 years of PCV7 use in the US, the vaccine
was estimated to have prevented 38 000 cases of IPD at
a cost of $112 000 per life-year saved [88]. When cases
of IPD avoided in unvaccinated individuals were
included, the total was 109 000 cases of IPD at a cost of
$7500 per life year saved. A review of European data [90]
identified 3 models from the UK and Norway in which
analyses were performed with and without including
indirect effects. Scenarios that included indirect effects
i.e., herd protection yielded lower costs per life year
gained (LYG) [91-93]. Considering cost per quality
adjusted life year (QALY), i.e., reduced morbidity in
addition to reduced mortality also consistently improved
the health-economic results in favor of vaccination with
PCV7 [94].
A subsequent Italian health economics analysis found
PCV13 to be highly cost effective compared to no vac-
cination and also to PCV7 [87]. This analysis included
the reduced risk of vaccinated individuals for IPD (sepsis
and meningitis), pneumonia (inpatient and outpatient),
meningitis, AOM (mild-moderate and severe) with or
without complications or sequellae. Reductions in quality
of life – essentially caused by sequelae of the diseases were
considered. The model assumed vaccination coverage of
80%, clinical efficacy of 97.4% against IPD caused by
PCV7 serotypes and 7% against all AOM. Assumed
reductions in visit rates among children <2 years of age
were 20% for AOM, 39% in cases of pneumonia and
hospitalization rates and 52.4% for all-cause pneumonia
[67,71,95-98]. Based on risk assessments for IPD, pneu-
monia, and otitis media, risks of hospital admission,
complications, direct plus indirect costs of treatment,
and mortality, the costs per life years saved and QALY
for PCV13 were dominant compared to PCV7, primar-
ily because it covers six additional serotypes and conse-
quently increased projected savings by preventing
infections caused by additional serotypes. In regions of
Italy where PCV7 had not been introduced prior to use
of PCV13 – Lombardia and Piemonte – the costs per
QALY were approximately 1300 to 2100 euro, respect-
ively. Sensitivity analysis showed that when vaccination
coverage was less than 80%, or if indirect effects were
excluded, the cost per QALY increased from 60 000 to
70 000 euro [87].
Pneumococcal vaccination in NIPs is a clinically- and
cost-effective strategy for PCV7 and potentially more fa-
vorable for higher-valency PCVs. Coverage of at least
80% of the target population provides sufficient herd
protection to gain economic benefits. Increase in inva-
sive disease caused by non-vaccine serotypes reduces the
overall direct effects of vaccination and offsets potential
positive herd protection benefits in unvaccinated indivi-
duals [79,87]. The higher valency pneumococcal vaccines
could have better net public health benefits than PCV-7
depending on the impact of broader serotype coverage.
Summary
Routine PCV7 vaccination has had a major impact on the
incidence of invasive and noninvasive pneumococcal dis-
eases (IPD, CAP, AOM) in children worldwide. Here we
present a European perspective at the end of the PCV7
vaccine era. PCV7 serotypes have greatly diminished
among IPD isolates. The prevalence of some non-PCV7
serotypes (e.g. 1, 7 F and 19A) has increased. The intro-
duction of pneumococcal vaccines containing a wider
range of serotypes will broaden serotype coverage and is
likely to have a positive and substantial impact on further
decreasing the burden of CAP disease in children. Further
reduction of pneumococcal carriage and early AOM infec-
tions may prevent the evolution of severe, complicated
AOM. Broader serotype coverage to reduce residual dis-
ease and resulting in herd protection against non-PCV7
serotypes would increase net public health benefits.
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